Genitourinary Cancers

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the potential of immunotherapy as an adjuvant treatment for patients with renal cell carcinoma (RCC).

The vision and dedication to training future urologic surgeons and advancing care by these giants of urology should never go unrecognized, underappreciated, or forgotten.

Brian Rini, MD, discusses additional adjuvant trials that have perplexed the field, what potential immunotherapy could have in this setting, and other obstacles to tackle in the renal cell carcinoma landscape.

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the results of a trial of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma.

Costas Lallas, MD, discusses the current role of immunotherapy for patients with genitourinary cancers, the potential for immunotherapy in combination with chemotherapy, and how the rise of immunotherapy affects all providers treating patients with these malignancies.

Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the side effects of cabozantinib (Cabometyx) plus immunotherapy agents in bladder cancer.

Updated phase II results from the KEYNOTE-052 trial showed that first-line treatment with pembrolizumab (Keytruda) produced a long-lasting response for patients with cisplatin-ineligible advanced urothelial cancer.

Moshe Ornstein, MD, discusses the obstacles physicians are facing with the use of immunotherapy for patients with renal cell carcinoma.

The Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization of tivozanib for adult patients with advanced renal cell carcinoma.

Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat plus pembrolizumab (Keytruda) in patients with metastatic renal cell carcinoma (RCC).

Jorge Garcia, MD, discusses how the field of bladder cancer has transformed with the FDA approval of pembrolizumab, and how oncologists should choose between 5 checkpoint inhibitors now available for the second-line setting and beyond.

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the potential of immunotherapy for patients with sarcomatoid renal cell carcinoma (RCC).

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the updated findings of the KEYNOTE-045 trial of pembrolizumab (Keytruda) in urothelial carcinoma.

Study results demonstrated that split-doses of gemcitabine and cisplatin as neoadjuvant chemotherapy for treating muscle-invasive bladder cancer has a good pathologic response with a high safety profile.

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the May 2017 FDA approval of pembrolizumab (Keytruda) in patients with urothelial carcinoma.

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice-president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses trials investigating immunotherapy in kidney cancer.

As manufacturers charge increasingly higher prices for new therapies and even well-established agents, payers have responded with pressure on practices to justify every cost, and Urology Clinics of North Texas, like many other independent practices, is caught in the middle.

Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses sequencing of immunotherapy for patients with bladder cancer.

Results from a blinded, independent data review confirmed previous results from the CABOSUN trial showing that treatment with cabozantinib (Cabometyx) extended progression-free survival compared with sunitinib (Sutent) for patients with previously untreated, intermediate- or poor-risk advanced renal cell carcinoma.

Christophe Massard, MD, PhD, discusses the latest developments with durvalumab (Imfinzi) in urothelial carcinoma.

Daniel P. Petrylak, MD, discusses the KEYNOTE-045 results and the next steps with pembrolizumab (Keytruda) in urothelial carcinoma.

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the IMmotion150 trial in renal cell carcinoma.

Simon Chowdhury, MD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses the combination of pembrolizumab (Keytruda) and pazopanib (Votrient) in patients with renal cell carcinoma (RCC).

Surgical resection, including cytoreductive nephrectomy, remains the standard of care for most patients with renal cell carcinoma, but many patients will have a recurrence, and could benefit from additional therapy.

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses a phase I study of pembrolizumab (Keytruda) plus axitinib (Inlyta) in patients with renal cell carcinoma (RCC).